We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prognostic Factors for All Types of Cancer Combined (ProFaCo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00704587
Recruitment Status : Completed
First Posted : June 25, 2008
Last Update Posted : April 6, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to investigate every possible applicability of flow cytometrical analysis in the intracellular detection of tumor-related material in activated macrophages in the broadest range of cancer types.

Condition or disease

Study Design

Study Type : Observational
Actual Enrollment : 520 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Flow Cytometrical Analysis of the Human Immune System to Assess Tumor-related Material Piling up in Activated Macrophages in All Relevant Cancer Types.
Study Start Date : November 2006
Primary Completion Date : June 2015
Study Completion Date : July 2015
Groups and Cohorts

Outcome Measures

Primary Outcome Measures :
  1. screening and followup [ Time Frame: 2 years ]

Biospecimen Retention:   Samples With DNA

white cells




Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
all patients diagnosed or suspected of cancerous conditions in the broadest sense of the word

Inclusion Criteria:

  • (Suspicion of) presence of cancer in the broadest sense of the word
  • Must be able to understand and sign written informed consent

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00704587

Atrium Medical Centre Parkstad
Heerlen, Limburg, Netherlands, 6401 PC
Maastricht University Medical Centre
Maastricht, Limburg, Netherlands, 6202 AZ
Sponsors and Collaborators
Atrium Medical Center
Maastricht University Medical Center
Principal Investigator: Dennis Japink, MD Atrium Medical Centre Parkstad, Heerlen
More Information

Responsible Party: Dennis Japink, drs, Atrium Medical Center
ClinicalTrials.gov Identifier: NCT00704587     History of Changes
Other Study ID Numbers: ProFaCo
METC 06-p-47
MEC 08-02-030
First Posted: June 25, 2008    Key Record Dates
Last Update Posted: April 6, 2016
Last Verified: April 2016

Keywords provided by Dennis Japink, Atrium Medical Center:
cancer occurence
cancer recurrence
neo-adjuvant treatment response measurement